2 news items
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
KA
15 May 24
.Research and development (R&D) expense: R&D expenses were $2.7 million for the three months ended
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
KA
21 Mar 24
. Research and development (R&D) expense: R&D expenses were $9.0 million
- Prev
- 1
- Next